CALCA and migraine disorder: Haghdoost et al. (2023) [74] and Messina et al. (2023) [75] recently reported a systematic review and network meta-analysis of phase three randomized controlled trials evaluating the efficacy, safety, and tolerability of CGRP monoclonal antibodies and gepants for the preventive treatment of migraine.